Effect of Interleukin-2 and Selenium on the Growth of Squamous Cell Carcinoma Cells

Abstract

OBJECTIVES: The objectives of this study were to determine whether the expression of the interleukin-2 (IL-2) receptors on squamous cell carcinoma cells can be enhanced in the presence of selenium (Se) and contribute to a greater retardation of tumor growth after locoregional therapy with IL-2.

STUDY DESIGN: The growth of the cells was studied after in vitro or dietary supplementation with Se in a murine model.

RESULTS: Treatment of established tumors in hosts supplemented with Se with peritumoral injections of IL-2 resulted in 50% reduction of tumor size, whereas treatment of early tumors resulted in 72.4% reduction. The effect was most likely related to a combination of enhanced immune responsiveness and enhanced IL-2 receptor expression on the tumor cells.

CONCLUSIONS AND SIGNIFICANCE: The data suggested that local immunotherapy with IL-2 in hosts supplemented with Se may represent an effective modality of treatment for the prevention of recurrences at the site of conventionally treated primary tumors, including tumors that do not express IL-2 receptors.

Get full access to this article

View all access options for this article.

References

1. Cancer Statistics 2000. CA Cancer J Clin 2000; 50:12.

2. Vokes

Weichselbaum

Lippman

, et al. Head and neck cancer. N Engl J Med 1993; 328:184–91.

3. Cortesina

Destefani

Giovarelli

, et al. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 1988; 62:2482–5.

4. Rivoltini

Passerini

Saraceno

, et al. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Cancer Res 1990; 50:5551–7.

5. Li

Jiang

Bishop

, et al. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Clin Cancer Res 1999; 5:1551–6.

6. Weidmann

Sacchi

Plaisance

, et al. Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumors in situ. Cancer Res 1992; 52:5963–70.

7. Roy

Kiremidjian-Schumacher

Wishe

, et al. Supplementation with selenium and human immune cell functions. I. Effect on lymphocyte proliferation and interleukin 2 receptor expression. Biol Trace Elem Res 1994; 41:103–14.

8. Roy

Kiremidjian-Schumacher

Wishe

, et al. Selenium supplementation enhances the expression of interleukin 2 receptor subunits and internalization of interleukin 2. Proc Soc Exp Biol Med 1993; 202:295–301.

9. Suminami

Kashii

Law

, et al. Molecular analysis of the IL-2 receptor β chain gene expressed in human tumor cells. Oncogene 1998; 16:1309–17.

10.

10. Sumareva

Ukrainsky

Kiremidjian-Schumacher

, et al. Effect of combined adoptive immunotherapy and radiotherapy on tumor growth. Rad Oncol Invest 1999; 7:22–9.

11.

11. Heo

Park

Hata

, et al. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 1990; 50:3681–90.

12.

12. Sacchi

Vitolo

Sedlmayr

, et al. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2. Int J Cancer 1991; 47:784–91.

13.

13. Whiteside

Miescher

Macdonald

, et al. Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors: A comparison between velocity sedimentation and discontinuous density gradients. J Immunol Methods 1986; 90:221–33.

14.

Whiteside

Tumor infiltrating lymphocytes in head and neck cancer. In: Lotzova

Herberman

, editors. Interleukin-2 and killer cells in cancer. Boca Raton (FL): CRC Press, Inc; 1994. p. 133–52.

15.

15. Whiteside

Letessier

Hirabayashi

, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 1993; 53:5654–62.

16.

Gutgsell

Malek

Formation of high affinity IL-2 receptors is dependent on a nonligand binding region of the α subunit. J Immunol 1994; 153:3899–907.

17.

17. Kiremidjian-Schumacher

Roy

Wishe

, et al. Supplementation with selenium and human immune cell functions. II. Effect on cytotoxic lymphocytes and natural killer cells. Bio Trace Elem Res 1994; 41:115–27.

18.

18. Harrison

Lanfear

, et al. Chemopreventive and growth inhibitory effects of selenium. Biomed Environ Sci 1997; 10:235–45.

19.

19. Kiremidjian-Schumacher

Roy

Glickman

, et al. Selenium and immunocompetence in patients with head and neck cancer. Biol Trace Elem Res 2000; 73:97–111.

20.

Combs

Clark

Turnbull

Reduction of cancer risk with oral supplement of selenium. Biomed Environ Sci 1997; 10:227–34.